IMM 0.81% 31.3¢ immutep limited

IMMP IMMUTEP Ltd PDUFA2022-03-19 LAG-3 Therapeutic Landscape...

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 536 Posts.
    lightbulb Created with Sketch. 64
    IMMP IMMUTEP Ltd PDUFA2022-03-19 LAG-3 Therapeutic Landscape Overview Company Program Preclinical Phase I Phase II Phase III Total Trials Patients Eftilagimod 10 4 14 967 (5) Alpha (6) 7 32 2 BMS Relatlimab 41 9,775 Merck & Co. Inc. Favezelimab 1 5 6 1066 PDUFA goal date March 19, 2022 Ieramilimab 1 4 5 952 Macrogenics Tebotelimab 3 3 6 1422 1 2 H-L Roche RO7247669 3 538 4 1 B.I. https://www.sec.gov/Archives/edgar/data/0001506184/000119312521332807/d214596dex991.htmWhenSat 19 Mar 2022


    Note extracted from FDA PDUFA calendar as above

 
watchlist Created with Sketch. Add IMM (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.